Trial Endpoints for Aspergillus and Rare Molds: Consensus Recommendations by the Mycoses Study Group Education and Research Consortium and the European Confederation of Medical Mycology

BACKGROUND: Invasive mold disease (IMD) remains a substantial cause of patient morbidity and mortality. Aspergillosis and mucormycosis remain the predominant infections encountered, although rare molds continue to emerge as important pathogens. Improvement in patient outcomes has been the result of progress in risk stratification, diagnostics, supportive care, antifungal therapy, and/or prophylaxis, yet substantial challenges remain, requiring the development of novel treatment strategies. Clinical trials evaluating treatment response are currently based on consensus criteria published in 2008. However, advances in clinical mycology and the broadening variety of mold diseases in clinical trials necessitate a revision of these criteria to ensure that adjudication of patient outcomes accurately captures responses to therapeutic intervention. METHODS: To tackle this task, an international expert panel nominated by the European Confederation of Medical Mycology (ECMM) and Mycoses Study Group Education and Research Consortium (MSGERC) was convened. RESULTS: The panel produced updated consensus guidance for assessing treatment responses and defining study outcomes in clinical trials of IMD in both adults and children. CONCLUSIONS: Along with guidance, potential pitfalls in assessing outcome, such as discordant clinical, radiologic, and/or mycologic data and areas for future research are discussed.

Authors

Institutions

Publication Details

Journal
Clinical Infectious Diseases
Published
2026-11-17
DOI
https://doi.org/10.1093/cid/ciag580
Citations
1
Primary Topic
Antifungal resistance and susceptibility
Type
article
Field-Weighted Citation Impact
3.05
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Trial Endpoints for Aspergillus and Rare Molds: Consensus Recommendations by the Mycoses Study Group Education and Research Consortium and the European Confederation of Medical Mycology

Márcio Nucci, Thomas J. Walsh, Carolynn Thomas Jones, Thomas F. Patterson et al.
1 citations
Clinical Infectious Diseases
Antifungal resistance and susceptibility
3.05
article

Trial Endpoints for Aspergillus and Rare Molds: Consensus Recommendations by the Mycoses Study Group Education and Research Consortium and the European Confederation of Medical Mycology

Márcio Nucci, Thomas J. Walsh, Carolynn Thomas Jones, Thomas F. Patterson, Jean‐Pierre Gangneux, Monica A. Slavin, Emmanuel Roilides, Dimitrios P. Kontoyiannis, Martin Hoenigl, Luis L. Ostrosky-Zeichner, Bart J. A. Rijnders, Cornelia Lass‐Flörl, George R. Thompson, Jessica S Little, Oliver A. Cornely, Ritesh Agarwal, Johan A. Maertens, Gerald G. McGwin, Peter G. Pappas, Matthew Goon
article en
1 citations

Abstract

BACKGROUND: Invasive mold disease (IMD) remains a substantial cause of patient morbidity and mortality. Aspergillosis and mucormycosis remain the predominant infections encountered, although rare molds continue to emerge as important pathogens. Improvement in patient outcomes has been the result of progress in risk stratification, diagnostics, supportive care, antifungal therapy, and/or prophylaxis, yet substantial challenges remain, requiring the development of novel treatment strategies. Clinical trials evaluating treatment response are currently based on consensus criteria published in 2008. However, advances in clinical mycology and the broadening variety of mold diseases in clinical trials necessitate a revision of these criteria to ensure that adjudication of patient outcomes accurately captures responses to therapeutic intervention. METHODS: To tackle this task, an international expert panel nominated by the European Confederation of Medical Mycology (ECMM) and Mycoses Study Group Education and Research Consortium (MSGERC) was convened. RESULTS: The panel produced updated consensus guidance for assessing treatment responses and defining study outcomes in clinical trials of IMD in both adults and children. CONCLUSIONS: Along with guidance, potential pitfalls in assessing outcome, such as discordant clinical, radiologic, and/or mycologic data and areas for future research are discussed.

Clinical Infectious Diseases
Universidade Federal do Rio de Janeiro (BR), University of Maryland, Baltimore (US), Brigham and Women's Hospital (US), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), Innsbruck Medical University (AT), Inserm (FR), École des Hautes Études en Santé Publique (FR), The University of Melbourne (AU), The University of Texas at San Antonio Health Science Center (US), University of Cologne (DE), Universität Innsbruck (AT), Medical University of Graz (AT), Aristotle University of Thessaloniki (GR), Universitair Ziekenhuis Leuven (BE), Peter MacCallum Cancer Centre (AU), Erasmus MC (NL), University of Alabama at Birmingham (US), Institut de Recherche en Santé, Environnement et Travail (FR), German Center for Infection Research (DE), Ippokrateio General Hospital of Thessaloniki (GR), BioTechMed-Graz (AT), Dana-Farber Cancer Institute (US), Cologne Excellence Cluster on Cellular Stress Responses in Aging Associated Diseases (DE), University Hospital Cologne (DE), Centre Hospitalier Universitaire de Rennes (FR), University of California Davis Medical Center (US), UAB Medicine (US), Post Graduate Institute of Medical Education and Research (IN), The Ohio State University (US), Université de Rennes (FR), University of California, Davis (US), The University of Texas Health Science Center at Houston (US), KU Leuven (BE)
Good health and well-being
Openalex Percentile: Top 17%
Antifungal resistance and susceptibility
3.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon